D
Myriad Genetics, Inc. MYGN
$10.18 -$0.34-3.23%
Recommendation
Sell
Prev Close
$10.52
Volume
819,596
Avg Vol (90D)
1,094,692
Market Cap
$960.57M
Dividend & Yield
--
52-Week Range
$9.76 - $29.30
P/E (TTM)
--
EPS (TTM)
-$1.41
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Myriad Genetics (NASDAQ:MYGN) Updates FY 2025 Earnings Guidance
3/7/2025 - MarketBeat
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of "Hold" from Analysts
3/7/2025 - MarketBeat
Piper Sandler Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price
3/5/2025 - MarketBeat
Piper Sandler Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price
3/4/2025 - Ticker Report
Myriad Genetics price target lowered by $2.50 at Piper Sandler, here's why
3/4/2025 - The Fly
Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Purchased by Fisher Asset Management LLC
3/4/2025 - Ticker Report
StockNews.com Downgrades Myriad Genetics (NASDAQ:MYGN) to Hold
3/4/2025 - Ticker Report
Myriad Genetics (NASDAQ:MYGN) Price Target Lowered to $11.00 at Bank of America
3/3/2025 - MarketBeat
Bank of America Lowers Myriad Genetics (NASDAQ:MYGN) Price Target to $11.00
3/3/2025 - Ticker Report
Myriad Genetics price target lowered by $2 at BofA, here's why
3/3/2025 - The Fly
Analysts Offer Insights on Healthcare Companies: Myriad Genetics (MYGN) and Veeva Systems (VEEV)
3/3/2025 - TipRanks Financial Blog
Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes
3/2/2025 - TipRanks Financial Blog
Myriad Genetics (NASDAQ:MYGN) Lowered to Hold Rating by StockNews.com
3/1/2025 - MarketBeat
Leerink Partnrs Predicts Myriad Genetics Q2 Earnings
2/28/2025 - MarketBeat
Myriad Genetics (MYGN, $11.06) RSI Indicator left the oversold zone on February 27, 2025
2/28/2025 - Tickeron - Stocks
Myriad Genetics Inc (MYGN) Partners with Gabbi to Enhance Breast Cancer Risk Assessment
2/27/2025 - GuruFocus
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk ...
2/27/2025 - GuruFocus
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
2/27/2025 - Globe Newswire
Myriad Genetics Full Year 2024 Earnings: EPS Misses Expectations
2/27/2025 - Simply Wall St
Myriad Genetics (MYGN, $11.56) Moving Average Convergence Divergence (MACD) Histogram turned negative on February 26, 2025
2/27/2025 - Tickeron - Stocks
Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results
2/26/2025 - Simply Wall St
Myriad Genetics (MYGN, $11.74) price exceeded its 50-day Moving Average on February 25, 2025
2/26/2025 - Tickeron - Technical Analysis
Myriad Genetics (MYGN, $11.74) entered Downtrend as Momentum indicator drops below 0 level on Feb 25, 2025
2/26/2025 - Tickeron - Technical Analysis
Myriad Genetics (MYGN) Stock Drops Due to Disappointing Results
2/25/2025 - GuruFocus
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
2/25/2025 - Benzinga
Income Statement
Total Revenue (TTM)
$837.60M
EBITDA (TTM)
-$26.70M
EBIT (TTM)
-$87.90M
Net Income (TTM)
-$127.30M
Balance Sheet
Total Assets (Q)
$1.03B
Total Debt (Q)
$140.30M
Total Liabilities (Q)
$326.50M
Book Value Per Share (Q)
$7.68
Cash Flow
Cash from Operations (TTM)
-$8.70M
Cash from Investing (TTM)
-$11.90M
Cash from Financing (TTM)
-$7.40M
Net Change in Cash (TTM)
-$29.00M
Filings
Filing Date
Friday, February 28, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.44
7-Day Total Return
-11.94%
30-Day Total Return
-20.22%
60-Day Total Return
-32.72%
90-Day Total Return
-53.32%
Year to Date Total Return
-24.59%
1-Year Total Return
-55.37%
2-Year Total Return
-53.09%
3-Year Total Return
-55.21%
5-Year Total Return
-32.45%
52-week Low
Feb 25, 2025 - $9.76
52-week High
Sep 18, 2024 - $29.30
Valuation
Market Cap
$960.57M - Small Cap
Enterprise Value
$998.47M
Price/Sales (TTM)
1.14
Price/Book (Q)
1.37
Dividends and Shares
Shares Outstanding
91.10M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.myriad.com
Phone Number
801 584 3600
Address
322 North 2200 West
Salt Lake City, UT 84116
Country
United States
Year Founded
1991
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops molecular tests in the United States and internationally. The company offers molecular diagnostic... more
NASDAQ 03/07/2025 4:00PM Eastern Quotes delayed
Weiss Ratings